Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

YK0901

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Yingkai Saiwei Biotech

Drug class:

TCR modulator, KRAS G12V inhibitor

Related drugs:

‹

TSC-204-C0702 (0)

mono TRuC-T CD70 cell therapy (0)

multiplexed MAGEA1/PRAME TCR-T cell therapy (0)

KRAS Mutated Antigen-specific TCR-T Cell Therapy (0)

mutant KRAS G12V-specific TCR transduced autologous T cell therapy (0)

FH-TCR-Tᴍsʟɴ (0)

HA-1 T TCR T Cell Immunotherapy (0)

MAGE A3 TCR (0)

NY-ESO-1 TCR (0)

NY-ESO-1 TCR-T cell therapy (0)

T-Plex-200-A0201/204-A0201 (0)

T-cell receptor therapy (0)

TSC-200-A0201 (0)

TSC-204-A0201 (0)

TSC-204-C0702 (0)

mono TRuC-T CD70 cell therapy (0)

multiplexed MAGEA1/PRAME TCR-T cell therapy (0)

KRAS Mutated Antigen-specific TCR-T Cell Therapy (0)

mutant KRAS G12V-specific TCR transduced autologous T cell therapy (0)

›

10ms

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor (clinicaltrials.gov)

P1, N=11, Not yet recruiting, Peking University

10 months ago

New P1 trial • Metastases

|

KRAS (KRAS proto-oncogene GTPase)

|

KRAS G12V • KRAS G12

|

cyclophosphamide • oxaliplatin • YK0901